These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12675332)

  • 41. Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children.
    Jeremy RJ; Kim S; Nozyce M; Nachman S; McIntosh K; Pelton SI; Yogev R; Wiznia A; Johnson GM; Krogstad P; Stanley K;
    Pediatrics; 2005 Feb; 115(2):380-7. PubMed ID: 15687448
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies.
    Lafeuillade A; Poggi C; Hittinger G; Counillon E; Emilie D
    J Infect Dis; 2003 Nov; 188(10):1426-32. PubMed ID: 14624367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
    Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F
    Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV-1 infection and low steady state viral loads.
    Callaway DS; Perelson AS
    Bull Math Biol; 2002 Jan; 64(1):29-64. PubMed ID: 11868336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Viral blip dynamics during highly active antiretroviral therapy.
    Di Mascio M; Markowitz M; Louie M; Hogan C; Hurley A; Chung C; Ho DD; Perelson AS
    J Virol; 2003 Nov; 77(22):12165-72. PubMed ID: 14581553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract.
    Cu-Uvin S; Hogan JW; Caliendo AM; Harwell J; Mayer KH; Carpenter CC;
    Clin Infect Dis; 2001 Sep; 33(6):894-6. PubMed ID: 11512096
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV-1 viral load blips are of limited clinical significance.
    Lee PK; Kieffer TL; Siliciano RF; Nettles RE
    J Antimicrob Chemother; 2006 May; 57(5):803-5. PubMed ID: 16533823
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels.
    Sörstedt E; Nilsson S; Blaxhult A; Gisslén M; Flamholc L; Sönnerborg A; Yilmaz A
    BMC Infect Dis; 2016 Jun; 16():305. PubMed ID: 27329293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative analysis of commercial assays for the detection and quantification of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in plasma from patients infected with HIV-1 subtype C.
    Hoesley CJ; Allen SA; Raper JL; Musonda R; Niu Y; Gao F; Squires KE; Aldrovandi GM
    Clin Infect Dis; 2002 Aug; 35(3):323-5. PubMed ID: 12115099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy.
    Jones LE; Perelson AS
    J Acquir Immune Defic Syndr; 2007 Aug; 45(5):483-93. PubMed ID: 17496565
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Trends in human immunodeficiency virus type 1 (HIV-1) load among HIV-1-infected children with hemophilia.
    Engels EA; Rosenberg PS; Katki H; Goedert JJ; Biggar RJ;
    J Infect Dis; 2001 Aug; 184(3):364-8. PubMed ID: 11443565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study.
    Young J; Rickenbach M; Calmy A; Bernasconi E; Staehelin C; Schmid P; Cavassini M; Battegay M; Günthard HF; Bucher HC;
    BMC Infect Dis; 2015 Sep; 15():382. PubMed ID: 26392270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Redefining the role of HIV viral load monitoring.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1998 Feb; 4(2):16-21. PubMed ID: 11365083
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.
    Hofstra LM; Mudrikova T; Stam AJ; Otto S; Tesselaar K; Nijhuis M; Wensing AM
    PLoS One; 2014; 9(10):e110749. PubMed ID: 25354368
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.
    Edén A; Nilsson S; Hagberg L; Fuchs D; Zetterberg H; Svennerholm B; Gisslén M
    J Infect Dis; 2016 Dec; 214(12):1822-1825. PubMed ID: 27683820
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis.
    Soulié C; Fourati S; Lambert-Niclot S; Tubiana R; Canestri A; Girard PM; Katlama C; Morand-Joubert L; Calvez V; Marcelin AG
    AIDS; 2010 Sep; 24(15):2412-4. PubMed ID: 21217205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Viral load blips.
    Proj Inf Perspect; 2000 Oct; (31):6. PubMed ID: 12171022
    [No Abstract]   [Full Text] [Related]  

  • 60. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance.
    Cohen Stuart JW; Wensing AM; Kovacs C; Righart M; de Jong D; Kaye S; Schuurman R; Visser CJ; Boucher CA
    J Acquir Immune Defic Syndr; 2001 Oct; 28(2):105-13. PubMed ID: 11588503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.